SEER logo

SEER INC

SEERNASDAQ
πŸ† #3920 by market capEarnings Nov 10US Equity
$1.93β–Ό $0.05 (βˆ’2.53%)
After hours Β· at close
πŸ””
Track SEER
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.5%
7dβ–Ό 1.8%
14dβ–Ό 5.6%
30dβ–Ό 10.2%
ytdβ–² 5.8%
1yβ–Ό 16.1%
🏦Market Cap
$107M
Small Cap
πŸ“ˆRevenue Growth (YoY)
15.6%
Healthy
πŸ“ŠGross Margin
46.3%
Healthy
πŸ’΅FCF Margin
-319.4%
Thin
βš–οΈP/S Ratio
8.0x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.92 – $2.00
52-Week Range
$1.55 – $2.38
Volume (shares)
12,690
Avg Volume (shares)
β€”
Shares Outstanding
55.4M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$16M
Last Q Revenue
$3M
P/E Ratio
-1.6
P/S Ratio
8.0x
EPS (TTM)
$-1.23
Dividend Yield
0.00%
Dilution (1yr)
βˆ’6.1%
SEER logo

SEER INC

SEER
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$16Mβ–² +15.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
49.7%β–² +1.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$78Mβ–Ό βˆ’22.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$46Mβ–Ό βˆ’6.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
57.4Mβ–Ό βˆ’6.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24Mβ–² +$9M YoY
StockOtter Β· stockotter.space

About SEER INC

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.